Royalty Pharma (STU:RPD) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:RPD Royalty Pharma PLC STU:RPD
70 GF Score
Price €48.98
GF Value €27.74
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Royalty Pharma Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:RPD vs ROIV, INCY, INSM: Short Interest Comparison

For the Biotechnology subindustry, Royalty Pharma's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Royalty Pharma Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Royalty Pharma's Short Interest distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's Short Interest falls into.


STU:RPD
70GF Score
Royalty Pharma PLC STU:RPD
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Royalty Pharma (STU:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €48.98 is trading 76.6% above its estimated GF Value™ of €27.74. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for STU:RPD:

  • Short Interest:
  • GF Value™: €27.74 vs. price of €48.98 (76.6% above fair value)
  • GF Score™: 70/100 with 9 warning signs

No single metric tells the full story. See the STU:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USARPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
70GF Score

Get the complete analysis for STU:RPD

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.98
Price
€27.74
GF Value